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222 Lipid lowering therapy
LIPID LOWERING THERAPY
Regression of atheroma seen with intravascular 
ultrasound: a placebo controlled study of the effect of 
gemfibrozil on peripheral atherosclerosis
A.N.S. Deaner, A.A. Cubukcu, J. Ball, S. Megary, M. Sivananthan,
G.J. Williams. Kiilingbeck Hospital, Leeds, UK
The Kiilingbeck Regression of Atheroma Study (KRAS) was a double blind 
placebo controlled study of the effect of gemfibrozil on atheroma in the aortoiliac 
arteries of patients with coronary artery disease and moderately raised lipids 
(mean total cholesterol = 6.8 mmoll"1). Serial cross-sectional images of these 
vessels were recorded using a 20 MHz intravascular ultrasound (IVUS) catheter 
during a controlled pull back in 39 patients (male 26, ages 38-70). Patients 
were given dietary advice and randomized to treatment with gemfibrozil 600 
mg bd or placebo. After treatment for a mean of 371 days the 31 patients 
(17 in gemfibrozil group) who completed the study underwent repeat imaging. 
Segments of arteries were matched using the position of bifurcations. 1144 
segments of arteries were matched and measurements of cross sectional area 
of atheroma made. Baseline demographics, physical and lipid data were well 
matched between the groups. In the gemfibrozil group significant reductions 
compared to the placebo group were seen in total cholesterol (9%, p « 0.03), 
triglycerides (55%, p = 0.0001) and LDLVHDL ratio (26%, p = 0,02), a significant 
increase in HDL cholesterol level (27% p = 0.05) was seen. No overall significant 
change in the mean cross-sectional area of atheroma was seen in the pEacebo 
group but there was a 10.3% decrease of this measurement in the gemfibrozil 
group (p = 0.011, 95% Cl = -5 .0  to -0 .8  mm2). Analysis of cross-sectional 
plaque area changes within individual patients showed significant (p < 0.05) 
regression in 6 gemfibrozil and 4 diet only patients and significant progression in
2 diet only patients. Analysis of the relationship between atheroma change and 
baseline risk factors baseline lipids and change in lipids in the gemfibrozil group, 
showed significant correlations of atheroma change with baseline systolic biood 
pressure, baseline Apolipoprotein B and baseline HDL cholesterol but not with 
change in any lipid parameter. Analysis of the relation of plaque type with 
severity of atheroma found that extent of calcification was related to severity of 
atheroma both between and within patients. Analysis of the pattern of atheroma 
change within patients showed regression most often occurred at the edge of 
plaques. By using IVUS we were able to show regression of atheroma in 
response to treatment with diet and gemfibrozil and provide new insights into 
the nature of atherosclerosis in vivo.
Simvastatin reduced coronary mortality and 
subsequent coronary and atherosclerosis-related 
events in patients who sustained a non-fatal 
myocardial infarction during the Scandinavian 
Simvastatin Survival Study (4S)
J. Kjekshus, T.R. Pedersen, A. Olsen, O. Faergeman. Scandinavian 
Simvastatin Study Group, University of Oslo, Norway
Treatment with simvastatin 20-40 mg daily in 4S reduced risk of death by 
30% (p = 0.0003), due to a 42% reduction in risk for CHD death. Risk of 
hospital-verified nonfatal myocardial infarction (Ml) was reduced by 37%. In the 
present analysis, the incidence of subsequent coronary mortality and coronary 
events was Investigated among the 757 patients who sustained one or more 
hospital-verified non-fatal Ml during the study (n = 300 in the simvastatin group, 
n = 457 in the placebo group). The numbers (percentages) of patients and 
events in the two treatment groups for different event categories are listed in 
the Table below:
Simvastatin (n = 300) Placebo (n = 457)
# events # patients # events # patients
CHD death 29 29 (10.1) 66 66(15.0)
Non-fatal Ml 95 55 (18.3) 154 105 (23.0)
CABG/PTCA 104 91 (30.3) 184 170 (37.2)
Atherosclerosis-related events 420 155 (51.7) 669 291 (63.7)
Although treatment group comparisons are not strictly valid (since patients 
were not randomly assigned to the groups analyzed) Cox proportional hazards 
analyses strongly suggest treatment effects within each of the above event 
categories. We conclude that cholesterol-lowering with simvastatin is effective 
In reducing subsequent CHD mortality and risk of CHD/atherosclerotic events 
in patients who sustain a nonfatal Ml during treatment. Therapy should be 
continued in such patients.
1289 The effect of red wine on experimental atherosclerosis
extension: lipid independent protection
P.L. da Luz, C.V. Serrano Jr., V.M. Yoshida, A.P. Chacra, M. Furtado,
S. Ferreira, P. Gutierrez, F. Pileggl. Insituto do Coragao, Hospital das Clinicas, 
Univ. Sao Pauio, Brazil
There is epidemiological evidence that red wine (RW) protects against atheroscle' 
rosis.
Methods and Results. To objectively test this hypothesis, New Zealand rabbits 
were given 1 % cholesterol diet for 12 weeks. Control animals received only diet; 
treated animals received 3.2 ml/kg/day of either RW or non-alcoholic products 
of wine (NAPW), in the drinking water. NAPW were obtained by extracting 
alcohol from RW at high temperatures. Macroscopic plaque extension was 
assessed by computerized planimetry after Sudam IV staining of excised 
aortas. Microscopic evaluation was based on intima/media (I/M) thickness ratio 
of 5 aortic segments after hematoxiiin/eosin staining. Lipids were measured by 
standard methods. LDL oxidizability was assessed in rabbits treated for 3-4 
weeks; lag-phase diene formation was measured by spectrophotometry after 
CuSCVLDL incubation. Diet produced a 22% increase in weight of all animals 
and about 20-fold increase in total cholesterol (TC). Results are shown in the 
table (Final TC and HDL in mg%. Lag phase in min.
Plaque (%Ao) I/M ratio TC HDL Lag phase
Control 69 ± 9 0.6 ±0.2 879 ±  38 19 ±  4 77 ±  6
RW 38 ±4* 0.1 ±0.09* 1102 ±  41 17 ±  7 82 ± 1 8
NAPW 47 ±12* 0,4 ±0.2* 824 ±  50 23 ± 6 84 ±  8
*p < 0.001 vs control, ANOVA).
Conclusion. Both RW and NAPW decreased plaque formation in hyper­
cholesterolemia rabbits despite high lipid plasma levels and unaltered LDL 
susceptibility to oxidation. Blockade of endothelial adhesion molecules expres­
sion by flavonolds, which are present in RW, may explain these results.
Evaluation of lipid-lowering therapy by functional 
assessment. A substudy of the Regression Growth 
Evaluation Statin Study (REGRESS)
W.R.M. Aengevaeren, G.J.H. Uijen, A.V.G, Bruschke1, J.W. Jukema1. T. van 
der Werf. Department of Cardiology, University Hospital Nijmegen;
11nteruniversltary Cardiology institute the Netherlands (ICIN), Utrecht, The 
Netherlands
In symptomatic men with significant coronary atherosclerosis treatment with 
pravastatin (prav.) in comparison with placebo (plat.) resulted in less progression 
of coronary atherosclerosis. The purpose of this study was to assess the effect 
of prav. on regional myocardial blood flow and on exercise parameters.
Methods: in Nijmegen 69 patients were randomised to prav. 40 mg o.d. 
or plac. according to the REGRESS protocol. Before and after two years of 
therapy regional myocardial blood flow was assessed by digital subtraction 
angiography after i.e. papaverine with video-densitometrie calculation of the 
hyperemic mean transit time (HMTT). Exercise testing was performed before 
and after two years of therapy in the medical management (M) stratum of the 
study, evaluating: exercise time (EXT) and Maximal ST-segment depression 
(MST).
Results; Complete follow-up after 2 years was available in 26 patients in the 
M, 10 In the PTCA (P) and 14 in the CABG (C) stratum, respectively. Effect 
analysis of prav, versus pfac. was based on 36 patients (M and P strata, PTCA 
vessels excluded). Regional myocardial perfusion was assessed in 40 regions 
in the prav. group and 31 regions in the plat, group. HMTT decreased by 0,17 
s (-5%) In the prav. group whereas HMTT increased by 0.36 s (+12%) in the 
plac. group (p = 0.02). In the M stratum EXT changed from 649 ± 192 to 632 
± 1 1 6 s (-1 7 s , p = 0.65) in the prav. group and from 759 ±  240 to 653 ±  224 
s (-106 s, p = 0.06) in the plac. group. ST max changed from 1.0 ± 1.0 to 0.7 
±1.1 mm (p -  0.13) in the prav. group and remained stable 0.7 ±  0.7 to 0.7 ±
0.7 mm in the plac. group.
in conclusion: These results indicate that the treatment with pravastatin 
favorably affects regional myocardial blood flow. There is a trend to reduced 
exercise induced ischemia and preserved exercise capacity.
